Anti-interleukin 5 strategies as a potential treatment for asthma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 9176543.
- Also identified by PMC identifier 1758563.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A paradigm shift, championed largely by cellular immunologists, has redefined asthma as an immune mediated phenomenon characterised by an interleukin 5 (IL-5) driven eosinophilic bronchitis. This change in emphasis has provoked intense interest in the possibility that inhibitors of IL-5 production, or antagonists of its activity, will provide a new generation of anti-asthma drugs.
Medical subject headings
- Asthma
- Eosinophilia
- Interleukin-5